A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2687-2694

  Banerji, Udai ^a,b   Van Doorn, Leni ^d   Papadatos Pastos, Dionysis ^a,b   Kristeleit, Rebecca ^a,b   Debnam, Phillip ^c   Tall, Matthew ^a   Stewart, Adam ^a   Raynaud, Florence ^a   Garrett, Michelle Dawn ^a   Toal, Martin ^c   Hooftman, Leon ^c   De Bono, Johann Sebastian ^a,b   Verweij, Jaap ^d   Eskens, Ferry A L M ^d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Chroma Therapeutics Ltd   (United Kingdom)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHR 3996; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACINAR CELL CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CANCER RESISTANCE; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEVER; HEADACHE; HEART ATRIUM FIBRILLATION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NAUSEA; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; ST SEGMENT DEPRESSION; T WAVE; TANDEM MASS SPECTROMETRY; THORAX PAIN; THROMBOCYTOPENIA; VOMITING;

ACETYLATION; ADMINISTRATION, ORAL; ADULT; AGED; AZABICYCLO COMPOUNDS; CLINICAL TRIALS, PHASE II AS TOPIC; FEMALE; FOLLOW-UP STUDIES; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; PYRIMIDINES; TISSUE DISTRIBUTION;

EID: 84860524932     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3165     Document Type: Article

References (19)

1. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5. (Pubitemid 30038513)
3. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009;277:8-21.
4. Balasubramanian S, Verner E, Buggy JJ. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009;280:211-21.
5. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28. (Pubitemid 34742100)
6. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485-91.
7. Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, et al. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0] hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem 2010;53:8663-78.
8. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9. (Pubitemid 351184977)
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
10. Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs 2011;20:1151-8.
11. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005;23:3923-31. (Pubitemid 46218695)
12. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006;12:4628-35. (Pubitemid 44297814)
13. Steele NL, Plumb JA, Vidal L, Tjornelund J, Knoblauch P, Rasmussen A, et al.Aphase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patientswith advanced solid tumors. Clin Cancer Res 2008;14:804-10. (Pubitemid 351231163)
14. Siu LL, Pili R, Duran I, Messersmith WA, Chen EX, Sullivan R, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008; 26:1940-7.
15. Gore L, Rothenberg ML, O'Bryant CL, Schultz MK, Sandler AB, Coffin D, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res 2008;14:4517-25.
16. Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 2010;3:2751-67.
17. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111:1060-6. (Pubitemid 351213383)
18. Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7.
19. Smith E, Walker B, Davenport E, Aronson L, Krige D, Hooftman L, et al. Inhibition of HDACs and Aminopeptidases is highly synergistic in myeloma cells resulting in cell death via the upregulation of BIRC3, a key mediator in NF-Kappa B signalling. Proc Ann Meet Am Soc Hematol 2009: Abstract 607.